Published on 18/03/2015 by admin
Filed under Dermatology
Last modified 22/04/2025
This article have been viewed 2153 times
Jillian W. Wong Millsop and John Y.M. Koo
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports
Psychogenic excoriation is a psychodermatologic condition in which patients participate in destructive scratching and picking of normal skin or skin with minor surface irregularities. Such behaviors may cause self-inflicted ulcers, abscesses, or scars that can ultimately become disfiguring. Although traditionally called ‘neurotic excoriation,’ the authors prefer the term ‘psychogenic excoriation’ since the underlying psychopathology may not be neurosis and may range from depression to obsessive compulsive disease to even psychosis. The traditional term, ‘neurotic excoriation,’ does our specialty a disservice, making dermatologists feel as if we know what is going on with the patient psychologically when the reality is that there is no way we can know what the underlying psychopathology is without carefully interviewing the patient regarding his or her mental status. Therefore, the authors recommend the following approach.
First, do not be fooled by the term ‘neurotic excoriation’; go beyond the skin to clearly ascertain the nature of the underlying psychopathology. Patient behavior may be associated with underlying depression, anxiety, obsessive compulsive disorder, psychosis or borderline personality disorder. Psychogenic excoriations may also be precipitated by emotional stress.
Second, before diagnosing a patient with psychogenic excoriation, it is important to rule out other psychodermatologic disorders, such as dermatitis artefacta (often associated with damage done with sharp objects rather than just fingernails, characteristic secrecy about the etiology of lesions and often associated with demanding and manipulative personality), or delusions of parasitosis (associated with delusional ideation, particularly the strongly held belief of organisms infesting the skin).
Finally, the appropriate treatment strategy can be determined based on the nature of the underlying psychopathology.
Because psychogenic excoriation is primarily a psychiatric disorder, for a dermatologist without time or training for psychotherapy, psychopharmacology could be the most feasible line of therapy.
If depression or anxiety is the underlying psychopathology, antidepressants and anti-anxiolytics are considered first-line treatment. One of the author’s (J.K.) preferred medication is the tricyclic antidepressant doxepin. There is an insufficient number of clinical trials demonstrating its efficacy in this condition, but doxepin is often useful due to its combined antidepressant and antihistaminic/antipruritic activity, which may be critical in disrupting the itch–scratch cycle. Doxepin is usually started at 10–25 mg at bedtime, with a gradual increase in dose of 10–25 mg every 2 to 4 weeks until the patient is taking up to 100 mg every evening, which is the typical effective antidepressant dose, particularly if the underlying psychopathology is major depression. If the patient requires even higher dosages, a maximum of up to 300 mg daily may be used, provided there are no side effects. Since doxepin can prolong the QT interval, a screening ECG is recommended for patients over age 55 or any patient with a past history of cardiac dysrhythmia. Sedation, syncope, seizures, weight gain, and orthostatic hypotension are other potential side effects.
Selective serotonin reuptake inhibitors (SSRIs) also have been shown in several reports to be effective in patients with psychogenic excoriation. These antidepressant drugs have better safety profiles than doxepin as they are less associated with sedation and cardiac conduction abnormalities. Other tricyclic antidepressants, such as clomipramine and amitriptyline, and various benzodiazepines are third-line therapies that should only be considered if the patient does not respond to more conventional treatments or cannot tolerate the side effects.
For treatment of underlying psychosis, antipsychotics can be effective. Pimozide, a traditional antipsychotic, olanzapine, an atypical antipsychotic, aripiprazole, a second-generation antipsychotic, and naltrexone, an opioid antagonist, may have a role for these patients with psychogenic excoriation.
As for borderline personality as the underlying psychopathology, psychotherapy is recommended. Psychotherapy and cognitive behavioral techniques, including aversion therapy and habit reversal treatments, have been reported in certain cases to be effective for this disorder, and can be used as adjunctive therapy for other underlying psychopathologies including those discussed above. There are two case reports of the efficacy of cognitive psychotherapy with laser irradiation of disfiguring skin lesions, as well as a case report on the efficacy of hypnosis to alleviate psychogenic excoriation.
There are other strategies for treatment which may further enhance systemic pharmacological treatments and psychotherapy. Treating associated infection and pruritus through the prudent use of antibiotics and antihistamines (oral or topical), respectively, and using topical corticosteroids may provide additional symptomatic benefit for patients with psychogenic excoriation. Lastly, a recent study demonstrated narrowband ultraviolet (NB-UVB) phototherapy may be helpful for psychogenic excoriation.
Close follow-up with a primary care physician or psychiatrist is recommended because of the high incidence of comorbid psychiatric conditions
Arnold LM, Auchenbach MB, McElroy SL. CNS Drugs 2001; 15: 351–9.
A review article that outlines the clinical features of psychogenic excoriation, comorbid psychiatric conditions, therapies, and potential criteria for diagnosis.
Arnold LM, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL, Morris EM. J Clin Psychiatry 1998; 59: 509–15.
Patients with psychogenic excoriations have a high prevalence of concurrent psychiatric illnesses such as mood disorders (68%), anxiety disorders (41%), somatoform disorders (21%), substance abuse (12%), and eating disorders (12%).
Koblenzer CS. Dermatol Clin 1996; 14: 447–55.
A good review article.
Mutasim DF, Adams BB. J Am Acad Dermatol 2009; 61: 611–13.
In a study of 50 patients with psychogenic excoriations compared to controls, the most significantly associated psychiatric comorbidities are depression and bipolar disorder.
Stein DJ, Hollander E. J Am Acad Dermatol 1992; 26: 237–42.
Patients with psychogenic excoriations often have obsessive–compulsive symptoms and may therefore respond to specific therapies aimed at this type of disorder.
Anetakis Poulos G, Algothani L, Bendo S, Zirwas MJ. J Clin Aesthet Dermatol 2012; 5: 63–4.
A 53-year-old woman with a history of schizophrenia, depression, hepatitis C, and diabetes was clinically misdiagnosed with neurotic excoriations instead of her true diagnosis – bullous pemphigoid.
It is essential that the diagnosis of psychogenic excoriations be made when other dermatologic diagnoses are definitively ruled out.
Koo J, Gambla C. Dermatol Clin 1996; 14: 509–24.
Describes in further detail the use of doxepin in psychogenic excoriations.
Harris BA, Sherertz EF, Flowers FP. Int J Dermatol 1987; 26: 541–3.
Case report of two patients who responded to doxepin 30 mg and 75 mg daily.
Kalivas J, Kalivas L, Gilman D, Hayden CT. Arch Dermatol 1996; 132: 589–90.
Sertraline was started at 25–50 mg daily and titrated upward to 100–200 mg daily as necessary, with improvements seen in 19 of 28 patients (68%) at an average of 4 weeks.
Biondi M, Arcangeli T, Petrucci RM. Psychother Psychosom 2000; 69: 165–6.
This is one case report demonstrating success with the SSRI paroxetine, which was thought to work secondary to its anticompulsive activity.
Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. J Clin Psychiatry 1997; 58: 341–7.
Fluoxetine was started at 20 mg daily and increased by 20 mg/week up to a maximum of 80 mg daily. Improvements in the treatment arm were statistically significant (based on an intent-to-treat analysis) at 6 weeks, with an average dose of 55 mg daily.
This trial is limited by a small sample (10 patients in the study arm and 11 in the placebo arm), a high dropout rate (40% in the fluoxetine group), and a study period of only 10 weeks, but the study substantiated earlier case reports.
Arnold LM, Mutasim DF, Dwight MM, Lamerson CL, Morris EM, McElroy SL. J Clin Psychopharmacol 1999; 19: 15–18.
Fluvoxamine was started at 25–50 mg daily and increased by up to 50 mg/week to a maximum of 300 mg daily for 12 weeks. Although all 14 participants demonstrated significant improvement in six of eight self-reported scales, the seven subjects who completed the study (50%) had improvement in only two of eight self-reported scales.
Pukadan D, Antony J, Mohandas E, Cyriac M, Smith G, Elias A. Aust NZ J Psychiatry 2008; 42: 435–6.
Escitalopram was administered at 10 mg/day to two patients: a 63-year-old woman with a 1-month history of diffuse pruritus and excessive excoriation, as well as major depressive disorder; and a 24-year-old man with a 10-year history of repeated nail biting and features of major depressive disorder. In both patients, scratching abated within 2 weeks.
Gupta MA, Gupta AK, Haberman HF. Compr Psychiatry 1986; 27: 381–6.
A case report of successful treatment using clomipramine 50 mg every evening for 6 months.
Fisher BK, Pearce KI. Cutis 1974; 14: 251–4.
Successful treatment with amitriptyline 50–75 mg daily was reported.
Fisher BK. Can Med Assoc J 1971; 105: 937–9.
This is a case report of the success of benzodiazepines prior to the availability of SSRIs. In general, benzodiazepines may be useful only if anxiety is the primary cause of psychogenic excoriations.
Duke EE. J Am Acad Dermatol 1983; 8: 845–50.
This case report primarily demonstrates the efficacy of pimozide (2 mg two or three times daily) in the treatment of post-herpetic neuralgia (eight patients) and psychogenic excoriations (two patients).
Blanch J, Grimalt F, Massana G, Navarro V. Br J Dermatol 2004; 151: 714–16.
This article describes a series of six patients with psychogenic excoriation who improved dramatically after treatment with olanzapine 2.5–10 mg daily.
Curtis AR, Richards RW. Ann Clin Psychiatry 2007; 19: 199–200.
This is a case report on the success of aripiprazole, a second-generation antipsychotic, and fluoxetine in an 18-year-old woman with psychogenic excoriations and obsessive–compulsive disorder.
Carter WG, 3rd, Shillcutt SD. J Clin Psychiatry 2006; 67: 1311.
This case report discusses the success of aripiprazole and venlafaxine in a 50-year-old woman with psychogenic excoriation, major depressive disorder, and generalized anxiety disorder who had been unresponsive to a serotonin–norepinephrine reuptake inhibitor alone.
Smith KC, Pittelkow MR. J Am Acad Dermatol 1989; 20: 860–1.
This article discusses the reported efficacy of naltrexone for psychogenic excoriations.
Fruensgaard K. Int J Dermatol 1991; 30: 198–203.
This article reports a positive impact of goal-directed psychotherapy in 22 patients followed over a period of approximately 5 years for psychogenic excoriations.
Bowes LE, Alster TS. Dermatol Surg 2004; 30: 934–8.
Two case reports of successful treatment of acne excoriée with a pulsed dye laser to improve the appearance of scars and ulcers, as well as cognitive psychotherapy to maintain improvement.
Kent A, Drummond LM. Clin Exp Dermatol 1989; 14: 163–4.
This is a case report on the success of habit reversal, a cognitive behavioral technique, for psychogenic excoriations.
Rosenbaum MS, Ayllon J. Behav Res Ther 1981; 19: 313–18.
This article reports a response to habit reversal therapy for neurodermatitis in three patients.
Ratcliffe R, Stein N. Behav Res Ther 1968; 6: 397–9.
This is a case report in which neurodermatitis secondary to psychogenic excoriation improved after aversion therapy, a cognitive behavioral technique.
Shenefelt PD. Am J Clin Hypn 2004; 46: 239–45.
In this case report, the acne excoriée in a pregnant woman was successfully alleviated through hypnotic suggestion.
Ozden MG, Aydin F, Senturk N, Bek Y, Canturk T, Turanli A. Photodermatol Photoimmunol Photomed 2010; 26: 162–4.
A prospective study assessing the effectiveness of phototherapy for psychogenic excoriation. Of the seven patients who completed the study and received NB-UVB, 50% or more reduction in clinical improvement scale scores was found in 71.4% (five of seven) of patients. The only side effects were xerosis and moderate erythema.
Treatment of Skin Disease Comprehensive Therapeutic Strategies 4e
WhatsApp us